Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 58

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 58
---
       — |     | $                                    | 20.33 |     | 01/03/2034             |     |                                                    |      — |        |     | $                                                       |         — |
|                           |     | 01/03/2024    |     |    -6 |     |                                                                     |       — |         |     |                                                                       |       — |        |     |                                                                                           |       — |     | $                                    |     — |     | —                      |     |                                                    | 53,720 |        |     | $                                                       | 1,094,814 |

(1) Each of the outstanding equity awards was granted pursuant to the 2015 Stock Incentive Plan (the “2015 Plan”) or the 2017 Equity Incentive Plan (the "2017 Plan").

(2) This column represents the fair value of a share of our common stock on the date of grant, as determined by our board of directors.

<div align='center'>-43-</div>

(3) This column represents the fair market value of the shares of our common stock as of December 31, 2024, based on the closing price of our common stock, as reported on the NASDAQ Global Select Market, of $20.38 per share on December 31, 2024.

(4) The shares subject to the unearned option will vest upon (i) the date on which the reported closing price of our common stock on Nasdaq or the New York Stock Exchange (or other national securities exchange) has, for 90 consecutive trading days, equaled or exceeded $80.00 per share (subject to adjustments for any stock split, reverse stock split or certain other changes in capitalization), with the first day of the 90-day measurement period no earlier than June 6, 2018, or (ii) the date on which we close a change of control transaction in which the stockholders receive consideration equal to no less than $80.00 per share (subject to adjustments for any stock split, reverse stock split or certain other changes in capitalization) in exchange for the sale of their capital stock.

(5) One-fourth of the total number of shares subject to the option vest on the one year anniversary of the grant date, and one forty-eighth of the total number of shares subject to the option vest monthly thereafter, subject to continued service to us through each such vesting date.

(6) Represents restricted stock units providing a contingent right to